EcoDrugPlus

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSACLG00000025911
Gene Symbol: F2R
4 Cross references
250 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSACLG00000025972
Gene Symbol: F2R
4 Cross references
249 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSACLG00000004577
Gene Symbol: F2R
3 Cross references
211 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSACLG00000006051
Gene Symbol: F3
3 Cross references
199 Possible Orthologues:

Coagulation Factor Vii-Like

Ensembl ID : ENSACLG00000004054
Gene Symbol: LOC113015535
3 Cross references
203 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSACLG00000004084
Gene Symbol: F10
1 Cross references
240 Possible Orthologues:

Coagulation Factor Xi-Like

Ensembl ID : ENSACLG00000003569
Gene Symbol: LOC113014558
2 Cross references
213 Possible Orthologues:

Coiled-Coil Domain Containing 6

Ensembl ID : ENSACLG00000019258
Gene Symbol: CCDC6
3 Cross references
208 Possible Orthologues:

Collagenase 3-Like

Ensembl ID : ENSACLG00000000704
Gene Symbol: LOC113030714
3 Cross references
273 Possible Orthologues:

Colony Stimulating Factor 1 Receptor, A

Ensembl ID : ENSACLG00000008970
Gene Symbol: CSF1RA
1 Cross references
207 Possible Orthologues:

Corticotropin Releasing Hormone Receptor 1

Ensembl ID : ENSACLG00000022257
Gene Symbol: CRHR1
3 Cross references
208 Possible Orthologues:

Cyclin D1

Ensembl ID : ENSACLG00000016341
Gene Symbol: CCND1
4 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).